Group LEadership

TIM MACLACHLAN

Tim MacLachlan is an Executive Director within the Department of Preclinical Safety at the Novartis Institutes of Biomedical Research leading efforts in the department with gene/cell therapies and biopharmaceuticals as well as all modalities targeting indications in the liver, kidney and hematology spaces. Prior to this Tim has held roles of increasing responsibility in safety assessment at Novartis, Genzyme and Curagen. Tim has been involved in several external toxicology groups including chair of the preclinical leadership committee of the Biotechnology Industry Organization, “Biosafe.” Tim received his Ph.D. from Thomas Jefferson University and performed his postdoctoral research at the University of Pennsylvania.

Sukhdeep Sahambi

Sukhdeep Sahambi is a Director within the Department of Preclinical Safety at the Novartis Institutes of Biomedical Research, providing strategic preclinical safety support in different disease areas and modalities.  Sukhdeep has worked in regulatory toxicology for more than a decade in different capacities in the Contract Research Organizations as well as at NIBR. She obtained her Ph.D. from Punjab Agricultural University in India, and performed her postdoctoral research at McGill University, Montreal, and Institut Armand-Frappier, INRS, Pointe-Claire, Quebec.

Sudheer Reddy

Sudheer Reddy (aka Sudheer Reddy Beedanagari) is currently working as a Director of Toxicology at Alexion, an Astra Zeneca Rare Disease Unit. At Alexion, he is responsible for leading the nonclinical safety evaluation and development strategy for multiple small molecule and biologics programs that are in development for Rare Disease indications. Prior to Alexion, Sudheer worked at Lexicon Pharmaceuticals, BMS, and Alkermes as a Toxicologist. Sudheer obtained his Ph.D. in Molecular Toxicology from UCLA.